XClose

Institute for Global Health

Home
Menu

UCL Centre for Clinical Research in Infection and Sexual Health - Research Projects

Study Short TitleFull TitleName of PIDatesStatus
SIREN (Sarscov2 Immunity & REinfection EvaluatioN)Impact of detectable anti-SARS-COV2 on the subsequent incidence of COVID-19 in healthcare workersAlejandro Arenas-PintoSeptember 2020 to September 2022Current
Analysing immune responses to vaccinationAnalysing humoral and cellular immune responses to vaccination during chronic infectionDimitra Peppa, Richard Gilson, Laura WatersOctober 2020 to October 2025Current
ICOSInternational SARS-CoV-2 Infection Observational StudyRichard Gilson27th May 2020 - (ongoing)Recruiting
Jenner IITemporal analysis of host immune responses and mechanisms impairing control of viral replication of during the course of HIV-1 infectionDimitra Peppa Recruiting
Chips+CHIPS+: Optimising the health of young people with HIV in their transition from paediatric to adult careAlistair Teague Recruiting
WISARDAN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENTEXPERIENCED HIV-1 INFECTED SUBJECTS VIROLOGICALLY SUPPRESSED WITH NNRTIS RESISTANCE MUTATION K103N.Laura Waters Recruiting
LAPTOPAn Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease – The Late Presenter Treatment Optimisation Study (LAPTOP)Robert Miller Recruiting
PIBIKA Phase IV Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutationsLaura Waters Recruiting
DOLOMITEDOLOMITE NEAT ID Network Study: A multi- site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant womenSherie Roedling Recruiting
INTUITInteraction Design for Trusted Sharing of Personal Health Data to Live Well with HIVJo Gibbs Recruiting
SEPACSEPAC SCREENING AND EARLY DETECTION TO PREVENT ANAL CANCER; DEVELOPMENT OF A BIOMARKER SCREENING TOOLRichard Gilson Recruiting
 
HIV Bioresource Fiona Burns Paused
Elite ControllersHIV elite controllers: Comprehensive assessment of host factors associated with HIV-1 elite controlRavi Gupta Paused
 
SALSAA Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressedSarah Pett In follow up
RiverRIVER - Research in Viral Eradication of HIV Reservoirs - a functional cure studySarah Pett In follow up
GS-1489GS-US-380-1489: A phase 3, randomised, Double Blind Study to Evaluate the Safety and Efficacy of GS9883/FTC/TAF vs. Triumeq in HIV-1 Infected, Antiretroviral Treatment Naïve AdultsLaura Waters In follow up
GS-1490GS-US-380-1490: A Phase 3, Randomised, Double Blind Study of the Safety and Efficacy of a Fixed Dose combination of GS9883/FTC/TAF vs. DOL/FTC/TAF in HIV-1 infected, Antiretroviral Treatment- Naïve AdultsLaura Waters In follow up
Merck 021MK-1439A-021: Double-Blind, Randomised Trial of Safety and Efficacy of FDC of TDF/3TC/doravirine (MK1439A) Once Daily vs Atripla® in Treatment Naïve HIV-positivesIan Williams In follow up
Merck 024MK-1439A-024: randomised study evaluating immediate vs deferred switch to  FDC of TDF/3TC/doravirine in patients stable and suppressed on a PI/r+2NRTIIan Williams In follow up
Merck 018A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1Infected Subjects.Ian Williams In follow up
POPPYThe POPPY (Pharmacokinetic and clinical Observations in PeoPle over fiftY) StudyCaroline Sabin In follow up
POPPY SleepPOPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep patternCaroline Sabin In follow up
STARTStrategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3Ian Williams In follow up
Eurosida 9EuroSIDA Cohort 9: Observational cohort study collecting clinical and demographic data for HIV-positive adults.Simon Edwards In follow up
Eurosida 10EuroSIDA Cohort X: Observational cohort study collecting clinical and demographic data for coinfected HIV/HCV positive adults.Simon Edwards In follow up
FLAIRFLAIR: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy and Safety of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected ART-Naive Adult ParticipantsSarah PettNov 2016 - currentIn follow up
DISCOVERGS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 InfectionRichard Gilson In follow up
TANGOA Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically supressed  Sarah PettApr 2018 - currentIn follow up
SAFETXTSafetxt: randomised controlled trial of safer sex intervention delivered through mobile phone messagingJohn Saunders In follow up
MAVMETMAVMET: a multicentre, 48 week randomised controlled factorial trial of adding Maraviroc and/or Metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapySarah Pett In follow up
PETRAMUnderstanding changes in treatment-related regional bone turnover using 18F-fluoride-PET/CT in HIV-1-infected men: PETRAM studySarah Pett In follow up
SAFER (UCLH) Nina Vora In follow up
 
PrEP IMPACT TrialPrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation.Richard Gilson Completed
POPPY LIVERHepatic steatosis in people living with HIV older than 50 years of age: The POPPY Hepatic Steatosis Sub-StudyAlejandro Arenas-Pinto Completed
ECLEAREarly administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)Erica Pool Completed
BESTTBESTT WOMEN's STUDY: Bone Evaluation in HIV positive women who switch from Truvada/NNRTI to TriumeqLaura WatersMay 2016 – Apr2020Completed
VITAVITA: A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosisRichard GilsonNov 2017 – Jun 2019Completed
BRIDGE-ITA randomised controlled trial to determine the effectiveness of bridging from emergency to regular contraception: The Bridge –it studyRichard Gilson Completed
PRIME FSHPRIME Ovarian Biomarker Study: Biomarkers of ovarian ageing in postmenopausal women living with HIV - a prevalence studyRob Miller/Shema Tariq Completed
PROUDPRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay menRichard Gilson Completed
H-ART 2 HEARTDeep Cardiovascular Phenotyping of People with HIV on Anti-Retroviral Therapy at risk of Heart DiseaseRichard Gilson Completed
GENAFRICAGenetic markers of kidney disease progression in people of African heritage in the UK CHIC cohortSarah Pett Completed
CIPHERCIPHER - study of cognitive function in HIV+ people.Lewis Haddow Completed
AMBERAMBER - randomised, double-blind study to evaluate efficacy and safety of DRV/cobicistat/FTC/TAF vs. DRV/cobicistat fixed dose combination plus Truvada®Laura Waters Completed
EMERALDEMERALD: randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDFLaura Waters Completed
FLU STUDYInfluenza acquisition in Health Care Workers who work on a dedicated influenza cohort wardRichard Gilson Completed
STOP HCV-1STOP HCV-1: Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease.Richard Gilson Completed
PARTNERPARTNER 2.0: A study in HIV sero-different partnerships to estimate the rate of transmission of HIV and to investigate factors associated with condom useRichard Gilson Completed
POSITIVE VOICESPositive Voices: The national survey of people living with HIVRichard Gilson Completed
STARTStrategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3Ian Williams Completed
HIPVACHIPvac: Randomised controlled trial of Imiquimod cream vs. podophyllotoxin in combination with quadrivalent HPV or control vaccination in the treatment and prevention of recurrence of anogenital warts.Richard GilsonFeb 2014 - currentCompleted
SYPHILIS TRANSCRIPTOMICSSyphilis Transcriptomics: Proof of concept study that aims to utilise next generation sequencing and transcriptomic approaches to understand infection with Treponema pallidumPatrick FrenchOct 2017 - currentCompleted
HPV SAMPLINGHPV Sampling Study: A study to evaluate the performance of human papillomavirus (HPV) DNA detection in residual specimens taken for Chlamydia trachomatis/Neisseria gonorrhoea nucleic acid amplification testing in men who have sex with men (MSM)Diarmuid NugentJan 2018 - currentCompleted
PRIMEPRIME: Quantitative and qualitative study that will exploring the impact of the menopause on HIV-positive women's health and wellbeingShema TariqJan 2016 – Oct 2017Completed
UK HDRDUK HIV Drug Resistance DatabaseDavid Dunn2001 – currentCompleted
GS-1823GS-US-292/1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult SubjectsLaura WatersSep 2016 – May 2018Completed
GS-1826GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 YearsLaura WatersAug 2016 – Mar 2018Completed
 
POPPY NEW WAVE Ian Williams Upcoming
EAGLE Richard Gilson Upcoming
RIO Sarah Pett Upcoming
DEVA Richard Gilson Upcoming
DOR-DOL Laura Waters Upcoming
PREP DLM Erica Pool Upcoming
SKIN CANCER QUESTIONNAIRE Alejandro Arenas-Pinto Upcoming
WEIGHT GAIN STUDY Alejandro Arenas-Pinto Upcoming
ANTIMICROBIAL PROPHYLAXIS SURVEY John Saunders Upcoming